These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8576907)

  • 1. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
    Willson TM; Cobb JE; Cowan DJ; Wiethe RW; Correa ID; Prakash SR; Beck KD; Moore LB; Kliewer SA; Lehmann JM
    J Med Chem; 1996 Feb; 39(3):665-8. PubMed ID: 8576907
    [No Abstract]   [Full Text] [Related]  

  • 2. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
    Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Henke BR
    J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
    [No Abstract]   [Full Text] [Related]  

  • 4. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
    Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
    Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
    Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
    J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
    Reddy KA; Lohray BB; Bhushan V; Bajji AC; Reddy KV; Reddy PR; Krishna TH; Rao IN; Jajoo HK; Rao NV; Chakrabarti R; Dileepkumar T; Rajagopalan R
    J Med Chem; 1999 Jun; 42(11):1927-40. PubMed ID: 10354401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
    Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
    J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
    Collins JL; Blanchard SG; Boswell GE; Charifson PS; Cobb JE; Henke BR; Hull-Ryde EA; Kazmierski WM; Lake DH; Leesnitzer LM; Lehmann J; Lenhard JM; Orband-Miller LA; Gray-Nunez Y; Parks DJ; Plunkett KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5037-54. PubMed ID: 9836621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-dependent stimulatory and inhibitory effect of troglitazone on insulin-induced fatty acid synthase expression and protein kinase B activity in 3T3-L1 adipocytes.
    Barthel A; Krüger KD; Roth RA; Joost HG
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):290-5. PubMed ID: 11919653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.
    Nolte RT; Wisely GB; Westin S; Cobb JE; Lambert MH; Kurokawa R; Rosenfeld MG; Willson TM; Glass CK; Milburn MV
    Nature; 1998 Sep; 395(6698):137-43. PubMed ID: 9744270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
    Young PW; Buckle DR; Cantello BC; Chapman H; Clapham JC; Coyle PJ; Haigh D; Hindley RM; Holder JC; Kallender H; Latter AJ; Lawrie KW; Mossakowska D; Murphy GJ; Roxbee Cox L; Smith SA
    J Pharmacol Exp Ther; 1998 Feb; 284(2):751-9. PubMed ID: 9454824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones.
    Kurogi Y
    Drug Des Discov; 1999 Aug; 16(2):109-18. PubMed ID: 10533807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
    Yanagisawa H; Takamura M; Yamada E; Fujita S; Fujiwara T; Yachi M; Isobe A; Hagisawa Y
    Bioorg Med Chem Lett; 2000 Feb; 10(4):373-5. PubMed ID: 10714503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P
    J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors.
    Johnson TE; Holloway MK; Vogel R; Rutledge SJ; Perkins JJ; Rodan GA; Schmidt A
    J Steroid Biochem Mol Biol; 1997; 63(1-3):1-8. PubMed ID: 9449199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth.
    Gupta RA; Wang D; Katkuri S; Wang H; Dey SK; DuBois RN
    Nat Med; 2004 Mar; 10(3):245-7. PubMed ID: 14758356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta.
    Wei ZL; Kozikowski AP
    J Org Chem; 2003 Nov; 68(23):9116-8. PubMed ID: 14604391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Perspective for development of insulin sensitizers].
    Kadowaki T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():566-72. PubMed ID: 12387052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.